Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab emtansine vs trastuzumab in HER2-positive primary breast cancer with residual disease after neoadjuvant therapy
CTR20150276Phase 3Completed
- Sponsor
- Royal DSM
- Start
- Apr 2015
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab emtansine in breast cancer, sponsored by Royal DSM. Started Apr 2015; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20150276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150276.